Figure 4. Pharmacological and functional assays and primary cell results.

A, The cytoskeletal drug cytochalasin D (cyto D) disrupts filamentous actin, leading to increase in compliance (over 40%) due to actin depolymerization in all cell types. B, As a functional assay using the chemoattractant fMLP, all differentiated cell types responded to fMLP in a manner consistent with their in vivo counterparts. C, Primary human neutrophils and CD34+-derived neutrophils are respectively about 3-fold and 4-fold more compliant than CD34+ primary human cord blood stem cells. The **** indicates a significant difference with a p value of <0.0001.